This post was originally published on this site
This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the “Securities Act”), and shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.
Contact Information
CorporateBioXcel TherapeuticsErik Kopp1.203.494.7062ekopp@bioxceltherapeutics.com
Investor RelationsBioXcel TherapeuticsBrennan Doyle1.475.355.8462bdoyle@bioxceltherapeutics.com
Media Russo Partners David Schull or Scott Stachowiak 1.858.717.2310 David.schull@russopartnersllc.com Scott.stachowiak@russopartnersllc.com
Source: OnkosXcel Therapeutics, LLC
Source: BioXcel Therapeutics
